Phase II Trial for Bertilimumab for Ulcerative Colitis Launched

Phase II Trial for Bertilimumab for Ulcerative Colitis Launched
Ulcerative colitisMassachusetts-based Immune Pharmaceuticals Inc., a company that specializes in creating antibody therapeutics for chronic inflammatory conditions, recently announced the start of participant screening for its Phase II clinical trial of one of their lead therapeutic products for ulcerative colitis, called Bertilimumab. Ulcerative colitis is a form of inflammatory bowel disease confined to the colon. It typically manifests as painful, bloody diarrhea, resulting in fatigue, weight loss, and even anemia. Bertilimumab is one of the first therapeutics in the pharmaceutical industry to employ biomarkers for a more personalized approach to designing treatment for patients. It is also indicated for two other diseases as well: Crohn's Disease and Bullous Pemphigoid, an auto-immune dermatological disease. The Chairman of the Institute for Digestive Diseases at Shaare Zedek Medical Center in Jerusalem, Israel, Eran Goldin, is the lead researcher for the clinical trial. It will be conducted across 10 sites and involves adult patients with active moderate to severe ulcerative colitis. Participants will be screened based on detected levels of eotaxin-1, a specific biomarker noted to be significantly elevated in select chronic inflammatory conditions. Bertilimumab has been shown in previous clinical trial settings to be capable of neutralizing eotaxin-1. News of the continued research and deve
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *